The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
The Hollywood star refused to appear on ITV's Good Morning Britain because of host Piers Morgan's comments about the women's marches.
The former Ukip leader has torn into the Labour leader as he backed his successor Paul Nuttall to claim the vacant Stoke Central seat.
The man, in his thirties, was found with stab injuries on the upper deck of a bus in Handsworth, Birmingham, on Monday night.